On April 22, the Food and Drug Administration (FDA) inspected Accugenix, LLC in Newark to assess drug quality assurance, according to data published on the FDA’s website.
The closing report found that Accugenix, LLC was not required to take any corrective actions for its management operations.
The FDA conducts inspections nationwide to evaluate whether workplaces and their products adhere to regulations designed to enhance public health. The agency then releases the findings to the public.
The agency’s website states that the FDA is mainly responsible for overseeing the safety and quality of human and animal drugs, biologics, medical devices and supplies, and tobacco products.
Information for this article was sourced from the U.S. Food and Drug Administration. The original data can be found here.
